Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid adsorbed + tetanus toxoid adsorbed + COVID-19 vaccine
- Development stage
- Unknown
- Lead developer
- The Kirby Institute
- Modality
- Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This entry describes the combination of vaccines administered within the CIRCUIT clinical trial (COVID-19 Booster Timing in Immunosuppressed Patients) sponsored by the Kirby Institute. The regimen includes an mRNA-based COVID-19 booster vaccine and a traditional protein-based diphtheria and tetanus toxoids (adsorbed) vaccine. The trial aims to determine the optimal timing for booster doses in patients initiating immunosuppressive therapy for hematological malignancies or autoimmune diseases, comparing immediate versus deferred (6-month) vaccination. The diphtheria/tetanus vaccine serves as a control to assess whether immune response patterns are specific to the mRNA platform or generalized across different vaccine types.
- Other names
- CIRCUIT trial vaccines
02
Targets
SARS-CoV-2 spikeDiphtheria toxin
Beyond the preview
Go deeper on diphtheria toxoid adsorbed + tetanus toxoid adsorbed + COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid adsorbed + tetanus toxoid adsorbed + COVID-19 vaccine.